cfr infographic09jun22

 

 

TABLE 1. FAMILY RECRUITMENT

  Male Female Total
       
Population-based Familiesa     13,188
Case probandsc, f 4,321 4,418 8,739
Affected relativese, f 339 380 719
Unaffected relativese, g 7,397 9,960 17,357
Spouse Controlsg, h 363 561 924
Unrelated control probandsg, i 2,071 2,204 4,275
Relatives of controls (Australia only)j 310 467 777
 Total population-based individuals 14,801 17,990 32,791
       
Clinic-based Familiesb     1,860
Affected probandsd, f 707 648 1,355
Unaffected probandsd, g 130 300 430
Affected relativese, f 444 467 912
Unaffected relativese, g 3,079 3,933 7,012
Total clinic-based individuals 4,360 5,348 9,709
       
Total Individuals 19,161 23,338 42,500
Total Families     15,048

 

 

TABLE 2. FAMILY DATA
    Male Female Total
A. Population-Based Case Familiesa      
Case Probandsc, f Baseline epidemiologic/risk factor survey datak 4,321 4,418  8,739 
  1st Follow-upepidemiologic/risk factor survey datal 2,652 2,980 5,632
  2nd Follow-up epidemiologic/risk factor survey datal 1,883 2,160 4,043
  3rd Follow-up epidemiologic/risk factor survey datal 1,240 1,491 2,731
  4th Follow-up epidemiologic/risk factor survey datal 548 701 1,249
  Food Frequency Questionnaire (FFQ) datam 2,094 2,406 4,500
  Blood/buccal samples 3,478 3,628 7,106
  Polyp material 18 11 29
  Tumor material: 3,574 3,452 7,026
        CRC tumor materialf, n 3,532 3,389 6,921
       Other (extracolonic) tumor materialo 98 153 251
  Clinical diagnosis and treatment datap 2,048 2,004 4,052
 Relativese Baseline epidemiologic/risk factor survey datak 7,736 10,340 18,076
  1st Follow-up epidemiologic/risk factor survey datal 6,055 8,344 14,399
  2nd Follow-up epidemiologic/risk factor survey datal 4745 6,690 11,435
  3rd Follow-up epidemiologic/risk factor survey datal 3280 4,671 7,951
  4th Follow-up epidemiologic/risk factor survey datal 1520 2,225 3,745
  Food Frequency Questionnaire (FFQ) datam 3274 4,619 7,893
  Blood/buccal samples 4115 5,817 9,932
  Polyp material 9 12 21
  Tumor material: 315 385 700
        CRC tumor materialf, n 248 261 509
        Other (extracolonic) tumor materialo 80 147 227
  Clinical diagnosis and treatment datap 52 54 106
Spouse Controlsh, g Baseline epidemiologic/risk factor survey datak 363 561 924
  1st Follow-up epidemiologic/risk factor survey datal 296 484 780
  2nd Follow-up epidemiologic/risk factor survey datal 233 398 631
  3rd Follow-up epidemiologic/risk factor survey datal 173 304 477
  4th Follow-up epidemiologic/risk factor survey datal 94 158 252
  Food Frequency Questionnaire (FFQ) datam 211 318 529
  Blood/buccal samples 259 409 668
  Polyp material 0 0 0
  Tumor material: 4 10 14
        CRC tumor materialf, n 1 4 5
        Other (extracolonic) tumor materialo 3 6 9
  Clinical diagnosis and treatment datap  0  0  0
B. Population-Based Control Families      
Probandsi Baseline epidemiologic/risk factor survey datak 2,071 2,204 4,275
  1st Follow-up epidemiologic/risk factor survey datal 668 591 1,259
  2nd Follow-up epidemiologic/risk factor survey datal 335 279 614
  3rd Follow-up epidemiologic/risk factor survey datal 0 0 0
  4th Follow-up epidemiologic/risk factor survey datal 0 0 0
  Food Frequency Questionnaire (FFQ) datam 1,151 1,024 2,175
  Blood/buccal samples 1,356 1,419 2,775
  Polyp material 0 0 0
  Tumor material: 0 0 0
        CRC tumor materialf, n 0 0 0
        Other (extracolonic) tumor materialo 0 0 0
  Clinical diagnosis and treatment datap 0 0 0
 Relativesj Baseline epidemiologic/risk factor survey datak 310 467 777
  1st Follow-up epidemiologic/risk factor survey datal 0 0 0
  2nd Follow-up epidemiologic/risk factor survey datal 0 0 0
  3rd Follow-up epidemiologic/risk factor survey datal 0 0 0
  4th Follow-up epidemiologic/risk factor survey datal 0 0 0
  Food Frequency Questionnaire (FFQ) datam 259 382 641
  Blood/buccal samples 5 5 10
  Polyp material 0 0 0
  Tumor material: 0 0 0
        CRC tumor materialf, n 0 0 0
        Other (extracolonic) tumor materialo 0 0 0
  Clinical diagnosis and treatment datap 0 0 0
         
C. Clinic-Based Familiesb      
Affected Probandsd, f Baseline epidemiologic/risk factor survey datak 707 648 1,355
  1st Follow-up epidemiologic/risk factor survey datal 511 502 1,013
  2nd Follow-up epidemiologic/risk factor survey datal 390 409 799
  3rd Follow-up epidemiologic/risk factor survey datal 240 254 494
  4th Follow-up epidemiologic/risk factor survey datal 75 96 171
  Food Frequency Questionnaire (FFQ) datam 236 252 488
  Blood/buccal samples 627 591 1,218
  Polyp material 21 24 45
  Tumor material: 590 538 1,128
        CRC tumor materialf, n 581 523 1,104
        Other (extracolonic) tumor materialo 77 98 175
  Clinical diagnosis and treatment datap 358 295 653
 Unaffected Probandsd, g Baseline epidemiologic/risk factor survey datak 130 300 430
  1st Follow-up epidemiologic/risk factor survey datal 122 277 399
  2nd Follow-up epidemiologic/risk factor survey datal 107 245 352
  3rd Follow-up epidemiologic/risk factor survey datal 64 139 203
  4th Follow-up epidemiologic/risk factor survey datal 20 48 68
  Food Frequency Questionnaire (FFQ) datam 72 183 255
  Blood/buccal samples 111 264 375
  Polyp material 18 34 52
  Tumor material: 30 85 115
        CRC tumor materialf, n 2 8 10
        Other (extracolonic) tumor materialo 28 81 109
  Clinical diagnosis and treatment datap 3 4 7
Relativese Baseline epidemiologic/risk factor survey datak 3,523 4,400 7,924
  1st Follow-up epidemiologic/risk factor survey datal 3,017 3,820 6,838
  2nd Follow-up epidemiologic/risk factor survey datal 2,483 3,206 5,690
  3rd Follow-up epidemiologic/risk factor survey datal 1,506 2,043 3,549
  4th Follow-up epidemiologic/risk factor survey datal 459 684 1,143
  Food Frequency Questionnaire (FFQ) datam 1,922 2,564 4,486
  Blood/buccal samples 3,007 3,860 6,868
  Polyp material 124 133 257
  Tumor material: 485 605 1,090
        CRC tumor materialf, n 338 375 713
        Other (extracolonic) tumor materialo 173 277 450
  Clinical diagnosis and treatment datap 15 6 21

 

a. Population-based families include colorectal cancer (CRC)-affected case probands ascertained through regional, state or provincial cancer registries and their CRC-affected and -unaffected family members (all CCFR sites); unrelated population-based control probands (Fred Hutch/Seattle, Sinai Health System/Ontario, Univ of Melbourne/Australia); spouse controls (Mayo Clinic, Univ of Hawaii, Univ of Melbourne/Australia), unaffected family member controls (Cedars-Sinai/USC consortium). 

b. Clinic-based families include CRC-affected and -unaffected probands ascertained through genetic and family cancer clinics and their CRC-affected and unaffected family members(Cleveland Clinic, Fred Hutch/Seattle, Mayo Clinic, Sinai Health System/Ontario, Univ of Melbourne/Australia).

c. Population-based colorectal cancer (CRC)-affected case probands ascertained through regional, state or provincial cancer registry.

d. Clinic-based probands, defined as the first family member ascertained through a genetic or family cancer clinic. Clinic-based probands may be CRC-affected or -unaffected at baseline epidemiologic/risk factors survey.

e. Relative of proband includes blood and non-blood related and may be CRC-affected or -unaffected.

f. CRC-affected at baseline epidemiologic/risk factors survey. CRC is defined as a malignant tumor in ICD-0 sites codes C18.0 - C18.9, C19.9, C20.0, C21.8,  and C26.0.

g. CRC-unaffected at baseline epidemiologic/risk factors survey. 

h. Spouse of population-based case proband recruited to serve as a control (Mayo Clinic, Univ of Hawaii, Univ of Melbourne/Australia, and UCSF).

i. Unrelated population-based control probands unaffected with CRC at baseline and ascertained through Medicare, driver's license files, telephone subscription lists or electoral roles (Fred Hutch/Seattle, Sinai Health System/Ontario, Univ of Melbourne/Australia). 

j. Family members of population-based controls (Australia). These may be CRC-affected or -unaffected.

k. Baseline epidemiologic/risk factor survey data (excluding proxy completion)

l. Follow-up epidemiologic/risk factor survey data. These are attempted every 4-5 years beginning in Phase II among Phase I enrollees (excluding population-based controls).

m. Food Frequency Questionnaire (FFQ). Hawaii FFQ version administered at baseline (Sinai Health System/Ontario, Univ of Hawaii, UCSF, Cedars-Sinai/USC consortium, Cleveland Clinic). Australia FFQ administered at baseline (Univ of Melbourne/Australia).

n. Individuals diagnosed with colorectal cancer and at least one colorectal tumor specimen obtained.

o. Individuals diagnosed with extracolonic cancer and at least one tumor specimen obtained. 

p. Clinical diagnosis and treatment data were collected approximately 4 years after CRC diagnosis for Phase I enrolled CRC-affected probands (all sites except Cedars-Sinai/USC consortium and UCSF).